DNA binding specificity and cytotoxicity of novel antitumor agent Ge132 derivatives
- 15 June 2005
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (12) , 2962-2965
- https://doi.org/10.1016/j.bmcl.2005.04.053
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Mechanisms of in Situ Activation for DNA-Targeting Antitumor AgentsChemical Reviews, 2002
- Allosteric, chiral-selective drug binding to DNAProceedings of the National Academy of Sciences, 2000
- Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282Medical Oncology, 1999
- Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibitionChemistry & Biology, 1999
- Drug—DNA interactionsCurrent Opinion in Structural Biology, 1998
- Regulation of gene expression by small moleculesNature, 1997
- DNA as a target for drug actionTrends in Pharmacological Sciences, 1988
- Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumoursBritish Journal of Cancer, 1985
- Crystal structure of "carboxyethylgermanium sesquioxide"Journal of the American Chemical Society, 1976
- Antimicrobial Activity of Organogermanium DerivativesNature, 1964